Upupcoco
2024-03-11

Let's gooooo

Press Release: Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research Annual Meeting. "We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting," said Dr. Steven Quay, Atossa's President and Chief Executive Officer. "While neoadjuvant therapy is effective and widely used across many cancer types, the current treatment options for premenopausal women diagnosed with ER+ breast cancer are sub-optimal. An effective and tolerable neoadjuvant therapy would transform the treatment approach in this setting, making surgery more effective and reducing the likelihood that the cancer will recur. There is growing excitement and understanding across the breast cancer community that -endoxifen, if shown to be safe and effective, would be a game changer for premenopausal women."
Press Release: Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet